Related Experiment Videos
Cefmenoxime. Clinical, bacteriologic, and pharmacologic studies.
The American Journal of Medicine
|July 1, 1984
Summary
Cefmenoxime, a third-generation cephalosporin, effectively treated various infections in 105 patients. This new antibiotic demonstrated good safety and efficacy, comparable to cefotaxime against most aerobic organisms.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Third-generation cephalosporins represent a critical class of antibiotics for treating bacterial infections.
- Evaluating new antibiotic agents is crucial for expanding treatment options and combating antimicrobial resistance.
Purpose of the Study:
- To assess the clinical efficacy and safety of cefmenoxime, a novel semisynthetic third-generation cephalosporin.
- To compare the in vitro activity of cefmenoxime with other established cephalosporins.
Main Methods:
- A clinical trial involving 105 patients with diverse infections including skin, pulmonary, urinary tract, and septicemia.
- In vitro susceptibility testing against 183 bacterial isolates using minimal inhibitory concentrations (MICs).
- Pharmacokinetic assessment of serum peak and trough levels at different intravenous dosages.
Main Results:
- Cefmenoxime demonstrated high clinical cure rates (86/105 infections).
- In vitro, cefmenoxime and cefotaxime showed comparable activity against most aerobic and facultative organisms, except Staphylococcus aureus.
- Mean peak serum levels of 84.1-106 mcg/ml and trough levels of 8.3-10.9 mcg/ml were observed.
Conclusions:
- Cefmenoxime is a safe and effective antibiotic for treating infections caused by susceptible gram-negative and gram-positive aerobic bacteria.
- Its in vitro activity and clinical outcomes support its use as a valuable therapeutic option.